Is ‘Maintenance Therapy’ in Metastatic Breast Cancer a Misnomer?

Podcast

Ron Piana, Executive Editor for Special Projects with the journal ONCOLOGY, spoke with nationally regarded breast cancer specialist, Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference.

Debu Tripathy, MD

Debu Tripathy, MD

Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference sheds light on his presentation, The Role of Maintenance Therapy for Metastatic Breast Cancer, truly a complicated and controversial topic.

-Interviewed by Ron Piana

Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content
Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

Ariana Pelosci
February 14th 2025
Article

Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer

Roman Fabbricatore
February 12th 2025
Article

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

ONCOLOGY Staff
February 9th 2025
Article

The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.

Hormone Therapy Confers Modest Breast Cancer Risk Even With Family History

Russ Conroy
February 8th 2025
Article

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.